- Home
- SLN vs KLTR Comparison
SLN vs KLTR Comparison
Compare SLN & KLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- KLTR
- Stock Information
- Founded
- SLN 1994
- KLTR 2006
- Country
- SLN United Kingdom
- KLTR United States
- Employees
- SLN N/A
- KLTR N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- KLTR EDP Services
- Sector
- SLN Health Care
- KLTR Technology
- Exchange
- SLN Nasdaq
- KLTR Nasdaq
- Market Cap
- SLN 299.4M
- KLTR 302.6M
- IPO Year
- SLN N/A
- KLTR 2021
- Fundamental
- Price
- SLN $4.81
- KLTR $1.63
- Analyst Decision
- SLN Buy
- KLTR Buy
- Analyst Count
- SLN 5
- KLTR 3
- Target Price
- SLN $32.60
- KLTR $2.83
- AVG Volume (30 Days)
- SLN 60.5K
- KLTR 271.4K
- Earning Date
- SLN 08-07-2025
- KLTR 08-07-2025
- Dividend Yield
- SLN N/A
- KLTR N/A
- EPS Growth
- SLN N/A
- KLTR N/A
- EPS
- SLN N/A
- KLTR N/A
- Revenue
- SLN $27,169,000.00
- KLTR $181,350,000.00
- Revenue This Year
- SLN N/A
- KLTR $3.43
- Revenue Next Year
- SLN N/A
- KLTR $2.96
- P/E Ratio
- SLN N/A
- KLTR N/A
- Revenue Growth
- SLN 22.28
- KLTR 2.56
- 52 Week Low
- SLN $1.97
- KLTR $1.06
- 52 Week High
- SLN $20.48
- KLTR $2.82
- Technical
- Relative Strength Index (RSI)
- SLN 34.88
- KLTR 48.46
- Support Level
- SLN $4.91
- KLTR $1.38
- Resistance Level
- SLN $5.34
- KLTR $1.66
- Average True Range (ATR)
- SLN 0.48
- KLTR 0.09
- MACD
- SLN -0.05
- KLTR 0.02
- Stochastic Oscillator
- SLN 0.71
- KLTR 85.71
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.